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Abstract 
Background: Limb g irdle muscular dystrophy (LGMD) is a neuromuscular 
abnormality with clin ical heterogeneity and various severity, where over 30 
subtypes have been identified. Meanwhile, molecular diagnosis of LGMD is not 
commonly  carried out in Indonesia. We present a large pedigree of familial LGMD, 
with over 14 years of fo llow-up.  
Case Presentation: A 12-year old female patient came with muscle weakness. She 
had toe walking since age of 6, followed by calf hypertrophy for over three years. 
Family h istory revealed complex consanguinity . Her younger sister and her parents’ 
cousin had similar condition, with the latter was already bedridden.  
Physical examination results were waddling gait, lordotic spine, and absent deep 
tendon reflexes. Muscle biopsy showed sign of dystrophic process. 
Immunoperoxidase staining of some proteins resulted normal. Single nucleotide 
polymorphis m (SNP) array in two siblings revealed homozygosity on chromosome 
15 containing CAPN3 gene of LGMD2A subtype. 
Recently, the patient is wheelchair bound and undergoes rehabilitation. Her sister is 
still able to walk with abnormal gait, while her parents’ cousin had passed away in 
age 55. From the multiple consanguinity, it could be concluded as autosomal 
recessive type LGMD.  
Conclusion: A large family with LGMD from Indonesia was presented with more 
than 14 years of care. Clinical diagnosis was made based on physical and additional 
examination, however molecular analysis for establishing definitive diagnosis is 
still limited. Further studies such as targeted or whole exome sequencing is 
warranted to elucidate the cause of disease. Long-term evaluation and supportive 
care, in addition to proper counseling may increase quality of life.  
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INTRODUCTION 
Limb girdle muscular dystrophy (LGMD) is a 
neuromuscular disorder with clinical heterogeneity 
and slow muscle deterioration progressivity. The 
overall prevalence of LGMD is estimated between 1 
in 14,500 to 45,000 indiv iduals, with more than 30 
subtypes have been known related to various severity 
and phenotypic spectrums. LGMD1 is a fo rm of 
autosomal dominant, with known subtypes including 
LGMD1A, LGMD1B, and LGMD1C. Meanwhile, 
LGMD 2 consists of various subtypes from LGMD2A 
to LGMD2Q, and recently found subtypes with rare 
prevalence from LGMD2R to LGMD2W. The most 
prevalent subtype among all is LGMD2A, which 
compromise 26.5-30% of all LGMD cases and is 
inherited in autosomal recessive manner.
1,2
 The 
disorder is due to deficiency of calpain-3 protein that 
involves in sarcomere remodeling process in the 
muscle.
3  
Lack  of  calpain-3  may  cause  a  significant  
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decrease in post-fusion incorporation of neonatal 
myosin heavy chain (nMHC), a developmental 
myogenic markers in muscle  fiber regeneration.
4
The 
molecular d iagnosis scope of limb gird le muscular 
dystrophy is not commonly performed in Indonesia. 
Thus, the etiological diagnosis of many 
neurodegenerative disorders remains overlooked by 
the clinicians. Nevertheless, clinical and supportive 
care of the affected family member are equally 
important. We present a large pedigree of familial 
limb  gird le muscular dystrophy, with more than 14 
years history of follow-up. This case, to the best of 
our knowledge, is the first reported cases of familial 
LGMD in Indonesia. 
 
CAS E PRES ENTATION 
A 12-years old female patient with muscle 
weakness was referred to the Center for Biomedical 
Research (CEBIOR) in 2002 for a genetic testing and 
genetic counseling regarding her condition. Since she 
was 6 years old, she had toe walking and was unable 
to squat. The condition was followed by pseudo 
hypertrophy of the calves for over three years. Her 
walking gait deteriorated, despite of undergoing 
Achilles tendon lengthening surgery to improve feet 
posture and gait. She experienced fatigable weakness, 
had  mild arm  weakness  and lordosis. There  were no  
 
 
 
 
 
 
cardiovascular or respiratory abnormalities. 
Family history revealed complex consanguinity, in 
which her parents are of second cousins’ marriage. 
Her younger sister had similar condition starting from 
age 7, while her parents’ cousin had started toe 
walking since age 20 and was already bedridden at 49 
years old. All three family members had elevated 
creatinine kinase (CK) level, where index patient and 
her sister showed significantly higher level (4,715 
U/L and 13,545 U/L [normal female value 145 U/L], 
respectively). Meanwhile, CK level of the uncle 
increased, but not as high as other family members 
upon checkup (278 U/L; normal male value 171 U/L). 
Multiple consanguinity of the family is shown in 
Figure 1. 
Physical examination revealed waddling gait, 
lordotic spine, and absent deep tendon reflexes, while  
other findings were unremarkable. Muscle biopsy 
showed sign of dystrophic process. 
Immunoperoxidase studies were performed on some 
proteins, i.e. Dystrophin 1, Dystrophin 2, Dystrophin 
3, Merosin, Adhalin, Beta Sarcoglycan, Gamma 
Sarcoglycan, Beta Dystroglycan, Emerin, Caveolin, 
and Dysferlin. All staining resulted in normal 
staining. SNP array on two siblings were carried out, 
with no copy number variat ions (CNVs) found. 
Meanwhile, further analysis revealed homozygosity 
on chromosome 15q15.1 (GRCh38) containing 
CAPN3 gene, which produces calpain-3 protein of 
LGMD2A subtype. 
 
 
 
 
 
Figure 1. Pedigree of family member with limb girdle muscular dystrophy. V:3 is index case with 
suspected LGMD2A. V:5 is her younger sister with starting similar condition. IV:22 is her uncle 
(parents’ cousin) who was bedridden. 
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Her younger sister occasionally walked on her 
toes, and received routine physiotherapy. There was 
no difficu lty on going up on a staircase. Meanwhile, 
her uncle had started toe walking at 20 years old. By 
the time of examination, he was already bedridden. 
Upon the latest follow up, the patient is now 26 
years old. She has already graduated from university, 
and is now wheelchair bound. Her younger sister is 
still able to walk with abnormal gait, while her 
parents’ cousin has passed away in age of 59 years 
old. The patient received short term steroid treatment, 
and until recently, she still undergoes physiotherapy. 
DISCUSS ION  
The most plausible subtype of  LGMD2A in this 
patient is first demonstrated by the multiple  
consanguinity in the family, which exp lains the 
autosomal recessive inheritance. LGMD2A onset 
ranges from 2 to 40 years old, with the average of 8-
15 years old.
2
 In this case, the age of onset were 6 
years old (index case), 9 years old (proband sibling), 
and 20 years old (proband uncle). Loss of ambulation 
typically occurred from 5 to 39 years. The long range 
of onset and slow progressivity distinguished this case 
to other autosomal recessive LGMD subtypes.On 
LGMD2B cases, there is similarly slow progressivity 
(10-20 years) but with different muscle involvement. 
Meanwhile in LGMD2C, there is a rapid  progressivity 
similar to Duchenne muscular dystrophy.
1 
Differences 
between subtypes of LGMD2 are shown on Table 1. 
 
 
 
 
LGMD2 
subtype Clinical features Muscle weakness Age onset Protein involvement  
LGMD2A No cardiac involvement, CK level 
varies  
Proximal 2-40 years Calpain 
LGMD2B Slow progressivity, no 
cardiomyopathy, very high CK 
level 
Distal and/or pelvic 
femoral 
17-23 years Dysferlin 
LGMD2C, D, 
E, F 
Severe progressivity, cardiac and 
respiratory involvement, very high 
CK 
Proximal 3-15 years Sarcoglycan 
LGMD2G Foot drop, moderately high CK 
level 
Proximal and distal 9-15 years Telethonin 
LGMD2H Facial weakness, waddling gait Proximal 1-9 years Tripartite motif containing 32 
LGMD2I Respiratory failure, 
cardiomyopathy, myalgia 
Proximal 1.5-27 years Fukutin related protein 
LGMD2J Cardiac and respiratory 
involvement 
Proximal and distal 5-25 years Titin 
LGMD2K Mild weakness, intellectual 
disability 
Proximal 1-3 years Protein-O-mannosyl transferase 
LGMD2L Predominantly affects male, no 
cardiac involvement  
Proximal pelvic 
femoral/distal lower 
limbs  
Late teens-
50 years 
Anoctamin 5 
LGMD2M Mild intellectual disability, 
cardiomyopathy 
Axial and proximal 4 months-4 
years 
Fukutin 
LGMD2N Calf hypertrophy Proximal 18 months Protein-O-mannosyl transferase 2 
LGMD2O Calf hypertrophy, severe myopia Proximal 12 years Protein-O-linked mannose β1,2  
N-acetylglucosaminyl transferase 
LGMD2P Intellectual disability, 
microcephaly, respiratory failure, 
cardiomyopathy 
Proximal First to the 
fourth 
decade of 
life 
Dystroglycan 
LGMD2Q Delayed motor milestone Proximal 2-3 years Plectin 
Table 1. Various subtypes of autosomal recessive LGMD. The clinical features, type of muscle weakness and age   onset, 
along with probable involvement of protein showed LGMD2A as the most possible cause of disorder.  
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LGMD2A is caused by missense, splice site, 
frameshift, o r nonsense mutation on calpain-3 gene 
(CAPN3) which located in 15q15-21. A missense 
mutation in the exon 22 of calpain-3 gene was shown 
in three cases of Brazilian and Amish consanguineous 
families.
5
 This region was particularly found 
homozygous in the two siblings, suggestive to the 
same cause of disorder. Phenotype manifestations are 
mainly in proximal muscles involvement, with 
specific biopsy results commonly found. There is no 
facial, card iac, and respiratory involvement on the 
LGMD2A subtype.
6
 
In this case, the uncle has lower level of CK serum 
(278 U/L) compared to other affected members, in the 
age of 45 years old. In the LGMD2A patients, CK 
serum is typically raised to 3-20 times higher than 
normal level. Decreasing CK serum level may be 
caused by the progressivity of disease and the 
increasing activity of muscle cell degeneration.
4
 
 
CONCLUS ION 
A large family with LGMD from Indonesia was 
presented with over 14 years of follow-up, which 
included physical examination, laboratory workups, 
rehabilitation and genetic counseling. Clin ical 
diagnosis was made based on physical and additional 
examination, however molecular analysis for 
establishing definit ive diagnosis is still limited. This 
case emphasizes the importance of genetic testing and 
counseling in Indonesia, especially in  patients with 
neurodegenerative disorders, where diagnostic 
workup remains as a challenge. To establish 
LGMD2A diagnosis, or to elucidate other possible 
cause of disease and protein involvement, fu rther 
studies such as targeted sequencing on CAPN3 gene 
or whole exome sequencing are warranted. Our long-
term evaluation and supportive care, in addition to 
proper genetic counseling may enhance the family 
quality of life. Proper diagnosis may shed light to 
future prevention on next generation, and may 
increase the efficacy of genetic counseling. 
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